About Us
R&D Overview
Collaborations
News & Events
Contact Us
Investors
Working For Chroma
Site Designed & Maintained by The B&M Group
Chroma Therapeutics is focused on harnessing the power of chromatin biology and novel drug accumulation approaches to discover and develop a new generation of targeted cancer and inflammation treatments.
Click to view Chroma's Pipeline
Final Opal Phase II Results Of Tosedostat Demonstrate Significant Response Rates In Elderly Patients With Treatment Refractory Or Relapsed Primary Or Secondary Acute Myeloid Leukemia
Chroma announces new positive Interim Phase II data for Tosedostat in AML OPAL study, revealed at ASCO
